Exceptional items comprise:
| XLS |
|
€ million |
2009 |
2008 |
|
Exit cost Raptiva® |
–39.7 |
– |
|
Divestment of natural substances business in Brazil |
10.6 |
–25.7 |
|
Release of provisions |
1.1 |
– |
|
Impairment losses on product technologies |
– |
–194.5 |
|
Impairment losses on licenses |
– |
–42.9 |
|
Impairment losses on goodwill |
– |
–41.7 |
|
Impairment losses on development technology |
– |
–20.2 |
|
Impairment losses on financial assets |
– |
–29.2 |
|
Restructuring |
– |
–45.8 |
|
Exceptional items |
–28.0 |
–400.0 |
The exceptional items for 2009 include expenses of € 39.7 million to withdraw the psoriasis drug Raptiva® after the suspension of marketing authorization. This item also includes income totaling € 10.6 million from the divestment of the natural substances business of the Performance & Life Science Chemicals division in Brazil, along with a € 1.1 million adjustment associated with a prior exceptional item.
back
